{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T04:27:34Z","timestamp":1768883254820,"version":"3.49.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:00:00Z","timestamp":1609632000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:00:00Z","timestamp":1609632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Sociedade Portuguesa de Reumatologia\/Pfizer","award":["PT2017_002"],"award-info":[{"award-number":["PT2017_002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s00296-020-04754-7","type":"journal-article","created":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T06:03:08Z","timestamp":1609653788000},"page":"311-318","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Increased short-term risk of cardiovascular events in inflammatory rheumatic diseases: results from a population-based cohort"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7339-0220","authenticated-orcid":false,"given":"Vital","family":"Da Silva Domingues","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2046-8017","authenticated-orcid":false,"given":"Ana M.","family":"Rodrigues","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6782-7481","authenticated-orcid":false,"given":"Sara S.","family":"Dias","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2375-9071","authenticated-orcid":false,"given":"Lu\u00eds","family":"Delgado","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8224-5121","authenticated-orcid":false,"given":"Ebrahim","family":"Barkoudah","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7024-4375","authenticated-orcid":false,"given":"Jaime","family":"Branco","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1894-4870","authenticated-orcid":false,"given":"Helena","family":"Canh\u00e3o","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,1,3]]},"reference":[{"issue":"7","key":"4754_CR1","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1093\/eurheartj\/ehx628","volume":"39","author":"A Timmis","year":"2017","unstructured":"Timmis A, Townsend N, Gale C et al (2017) ESC scientific document group. European society of cardiology: cardiovascular disease statistics 2017. Eur Heart J 39(7):508\u2013579. https:\/\/doi.org\/10.1093\/eurheartj\/ehx628","journal-title":"Eur Heart J"},{"issue":"10","key":"4754_CR2","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","volume":"139","author":"EJ Benjamin","year":"2019","unstructured":"Benjamin EJ, Muntner P, Alonso A et al (2019) American heart association council on epidemiology and prevention statistics committee and stroke statistics subcommittee. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation 139(10):e56\u2013e528. https:\/\/doi.org\/10.1161\/CIR.0000000000000659","journal-title":"Circulation"},{"issue":"29","key":"4754_CR3","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"MF Piepoli","year":"2016","unstructured":"Piepoli MF, Hoes AW, Agewall S et al (2016) 2016 European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 37(29):2315\u20132381. https:\/\/doi.org\/10.1093\/eurheartj\/ehw106","journal-title":"Eur Heart J"},{"issue":"11","key":"4754_CR4","doi-asserted-by":"publisher","first-page":"e596","DOI":"10.1161\/CIR.0000000000000678","volume":"140","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA et al (2019) 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the american college of cardiology\/american heart association task force on clinical practice guidelines. Circulation 140(11):e596\u2013e646. https:\/\/doi.org\/10.1161\/CIR.0000000000000678","journal-title":"Circulation"},{"issue":"1","key":"4754_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12916-019-1340-7","volume":"17","author":"JA Damen","year":"2019","unstructured":"Damen JA, Pajouheshnia R, Heus P et al (2019) Performance of the Framingham risk models and pooled cohort equations for predicting 10-year risk of cardiovascular disease: a systematic review and meta-analysis. BMC Med 17(1):109. https:\/\/doi.org\/10.1186\/s12916-019-1340-7","journal-title":"BMC Med"},{"issue":"9921","key":"4754_CR6","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/S0140-6736(13)61752-3","volume":"383","author":"SS Mahmood","year":"2014","unstructured":"Mahmood SS, Levy D, Vasan RS, Wang TJ (2014) The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. Lancet 383(9921):999\u20131008. https:\/\/doi.org\/10.1016\/S0140-6736(13)61752-3","journal-title":"Lancet"},{"issue":"11","key":"4754_CR7","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41569-019-0202-5","volume":"16","author":"C Andersson","year":"2019","unstructured":"Andersson C, Johnson AD, Benjamin EJ et al (2019) 70-year legacy of the Framingham Heart Study. Nat Rev Cardiol 16(11):687\u2013698. https:\/\/doi.org\/10.1038\/s41569-019-0202-5","journal-title":"Nat Rev Cardiol"},{"issue":"10","key":"4754_CR8","doi-asserted-by":"publisher","first-page":"e1288","DOI":"10.1016\/S2214-109X(19)30365-1","volume":"7","author":"F Farzadfar","year":"2019","unstructured":"Farzadfar F (2019) Cardiovascular disease risk prediction models: challenges and perspectives. Lancet Glob Health 7(10):e1288\u2013e1289. https:\/\/doi.org\/10.1016\/S2214-109X(19)30365-1","journal-title":"Lancet Glob Health"},{"issue":"18","key":"4754_CR9","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1161\/01.cir.97.18.1837","volume":"97","author":"PW Wilson","year":"1998","unstructured":"Wilson PW, D\u2019Agostino RB, Levy D et al (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97(18):1837\u20131847. https:\/\/doi.org\/10.1161\/01.cir.97.18.1837","journal-title":"Circulation"},{"key":"4754_CR10","doi-asserted-by":"publisher","DOI":"10.23880\/OAJC-16000124","author":"GHR Rao","year":"2018","unstructured":"Rao GHR (2018) Risk scores for acute vascular events: expectations and limitations. OAJC. https:\/\/doi.org\/10.23880\/OAJC-16000124","journal-title":"OAJC"},{"issue":"2","key":"4754_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1541-9215.2007.06350.x","volume":"5","author":"BA Hemann","year":"2007","unstructured":"Hemann BA, Bimson WF, Taylor AJ (2007) The Framingham risk score: an appraisal of its benefits and limitations. Am Heart Hosp J 5(2):91\u201396. https:\/\/doi.org\/10.1111\/j.1541-9215.2007.06350.x","journal-title":"Am Heart Hosp J"},{"issue":"4","key":"4754_CR12","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1136\/annrheumdis-2014-206879","volume":"75","author":"EEA Arts","year":"2016","unstructured":"Arts EEA, Popa CD, Den Broeder AA et al (2016) Prediction of cardiovascular risk in rheumatoid arthritis: performance of original and adapted SCORE algorithms. Ann Rheum Dis 75(4):674\u2013680. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206879","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"4754_CR13","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.amjcard.2012.03.044","volume":"110","author":"CS Crowson","year":"2012","unstructured":"Crowson CS, Matteson EL, Roger VL et al (2012) Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am J Cardiol 110(3):420\u2013424. https:\/\/doi.org\/10.1016\/j.amjcard.2012.03.044","journal-title":"Am J Cardiol"},{"issue":"6","key":"4754_CR14","doi-asserted-by":"publisher","first-page":"928","DOI":"10.3899\/jrheum.190261","volume":"47","author":"K Colaco","year":"2020","unstructured":"Colaco K, Ocampo V, Ayala AP et al (2020) Predictive utility of cardiovascular risk prediction algorithms in inflammatory rheumatic diseases: a systematic review. J Rheumatol 47(6):928\u2013938. https:\/\/doi.org\/10.3899\/jrheum.190261","journal-title":"J Rheumatol"},{"issue":"1","key":"4754_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","volume":"76","author":"R Agca","year":"2016","unstructured":"Agca R, Heslinga SC, Rollefstad S et al (2016) EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update. Ann Rheum Dis 76(1):17\u201328. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209775","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4754_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00296-016-3619-8","volume":"37","author":"AY Gasparyan","year":"2017","unstructured":"Gasparyan AY (2017) Cardiovascular risk and inflammation in rheumatic diseases. Rheumatol Int 37(1):1\u20132. https:\/\/doi.org\/10.1007\/s00296-016-3619-8","journal-title":"Rheumatol Int"},{"issue":"7","key":"4754_CR17","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s00296-018-4053-x","volume":"38","author":"M Biskup","year":"2018","unstructured":"Biskup M, Biskup W, Majdan M, Targo\u0144ska-St\u0119pniak B (2018) Cardiovascular system changes in rheumatoid arthritis patients with continued low disease activity. Rheumatol Int 38(7):1207\u20131215. https:\/\/doi.org\/10.1007\/s00296-018-4053-x","journal-title":"Rheumatol Int"},{"issue":"12","key":"4754_CR18","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/nrrheum.2015.112","volume":"11","author":"MT Nurmohamed","year":"2015","unstructured":"Nurmohamed MT, Heslinga M, Kitas GD (2015) Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol 11(12):693\u2013704. https:\/\/doi.org\/10.1038\/nrrheum.2015.112","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"4754_CR19","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1136\/annrheumdis-2013-204531","volume":"74","author":"EEA Arts","year":"2015","unstructured":"Arts EEA, Fransen J, den Broeder AA et al (2015) The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients. Ann Rheum Dis 74(6):998\u20131003. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204531","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"4754_CR20","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1136\/annrheumdis-2014-206411","volume":"75","author":"E Myasoedova","year":"2016","unstructured":"Myasoedova E, Chandran A, Ilhan B et al (2016) The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease. Ann Rheum Dis 75(3):560\u2013565. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206411","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"4754_CR21","doi-asserted-by":"publisher","first-page":"e0205506","DOI":"10.1371\/journal.pone.0205506","volume":"13","author":"L Navarini","year":"2018","unstructured":"Navarini L, Margiotta DPE, Caso F et al (2018) Performances of five risk algorithms in predicting cardiovascular events in patients with Psoriatic Arthritis: an Italian bicentric study. PLoS ONE 13(10):e0205506. https:\/\/doi.org\/10.1371\/journal.pone.0205506","journal-title":"PLoS ONE"},{"issue":"1","key":"4754_CR22","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13075-020-02178-z","volume":"22","author":"G Wibetoe","year":"2020","unstructured":"Wibetoe G, Sexton J, Ikdahl E et al (2020) Prediction of cardiovascular events in rheumatoid arthritis using risk age calculations: evaluation of concordance across risk age models. Arthritis Res Ther 22(1):90. https:\/\/doi.org\/10.1186\/s13075-020-02178-z","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"4754_CR23","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1093\/rheumatology\/kex038","volume":"56","author":"CS Crowson","year":"2017","unstructured":"Crowson CS, Gabriel SE, Semb AG et al (2017) Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries. Rheumatology (Oxford) 56(7):1102\u20131110. https:\/\/doi.org\/10.1093\/rheumatology\/kex038","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"4754_CR24","first-page":"384","volume":"35","author":"S Ramiro","year":"2010","unstructured":"Ramiro S, Canh\u00e3o H, Branco JC (2010) EpiReumaPt Protocol\u2014Portuguese epidemiologic study of the rheumatic diseases. Acta Reumatol Port 35(3):384\u2013390","journal-title":"Acta Reumatol Port"},{"issue":"2","key":"4754_CR25","first-page":"110","volume":"40","author":"AM Rodrigues","year":"2015","unstructured":"Rodrigues AM, Gouveia N, da Costa LP et al (2015) EpiReumaPt- the study of rheumatic and musculoskeletal diseases in Portugal: a detailed view of the methodology. Acta Reumatol Port 40(2):110\u2013124","journal-title":"Acta Reumatol Port"},{"issue":"9","key":"4754_CR26","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC (1997) Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725. https:\/\/doi.org\/10.1002\/art.1780400928","journal-title":"Arthritis Rheum"},{"issue":"9","key":"4754_CR27","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"269","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Against Rheumatism collaborative Rheumatology\/European League initiative. Ann Rheum Dis 269(9):1580\u20131588. https:\/\/doi.org\/10.1136\/ard.2010.138461","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4754_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.2010.133645","volume":"70","author":"M Rudwaleit","year":"2011","unstructured":"Rudwaleit M, Van Der Heijde D, Landew\u00e9 R et al (2011) The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70(1):25\u201331. https:\/\/doi.org\/10.1136\/ard.2010.133645","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"4754_CR29","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1136\/ard.38.5.434","volume":"38","author":"HA Bird","year":"1979","unstructured":"Bird HA, Esselinckx W, Dixon AS et al (1979) An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis 38(5):434\u2013439. https:\/\/doi.org\/10.1136\/ard.38.5.434","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"4754_CR30","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2307\/2529990","volume":"36","author":"JL Fleiss","year":"1980","unstructured":"Fleiss JL, Tytun A, Ury HK (1980) A simple approximation for calculating sample sizes for comparing independent proportions. Biometrics 36(2):343\u2013346. https:\/\/doi.org\/10.2307\/2529990","journal-title":"Biometrics"},{"issue":"2","key":"4754_CR31","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1136\/annrheumdis-2014-205675","volume":"74","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Yu Y, Haynes K et al (2015) Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis 74(2):326\u2013332. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205675","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"4754_CR32","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1136\/annrheumdis-2016-210973","volume":"76","author":"EV Arkema","year":"2017","unstructured":"Arkema EV, Svenungsson E, Von Euler M et al (2017) Stroke in systemic lupus erythematosus: a Swedish population-based cohort study. Ann Rheum Dis 76(9):1544\u20131549. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210973","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"4754_CR33","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1093\/rheumatology\/kew475","volume":"56","author":"ML Hermansen","year":"2017","unstructured":"Hermansen ML, Lindhardsen J, Torp-Pedersen C et al (2017) The risk of cardiovascular morbidity and cardiovascular mortality in systemic lupus erythematosus and lupus nephritis: a Danish nationwide population-based cohort study. Rheumatology (Oxford) 56(5):709\u2013715. https:\/\/doi.org\/10.1093\/rheumatology\/kew475","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"4754_CR34","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.reuma.2017.06.002","volume":"15","author":"A Balsa","year":"2019","unstructured":"Balsa A, Lojo-Oliveira L, Alperi-L\u00f3pez M et al (2019) Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring in clinical practice: the spanish cohort of the COMORA study. Reumatol Clin 15(2):102\u2013108. https:\/\/doi.org\/10.1016\/j.reuma.2017.06.002","journal-title":"Reumatol Clin"},{"issue":"5","key":"4754_CR35","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1093\/oxfordjournals.aje.a009122","volume":"145","author":"S Manzi","year":"1997","unstructured":"Manzi S, Meilahn EN, Rairie JE et al (1997) Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 145(5):408\u2013415. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a009122","journal-title":"Am J Epidemiol"},{"issue":"5","key":"4754_CR36","first-page":"813","volume":"34","author":"J van den Hoek","year":"2016","unstructured":"van den Hoek J, Roorda LD, Boshuizen HC et al (2016) Trend in and predictors for cardiovascular mortality in patients with rheumatoid arthritis over a period of 15 years: a prospective cohort study. Clin Exp Rheumatol 34(5):813\u2013819","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"4754_CR37","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3899\/jrheum.180726","volume":"47","author":"R Agca","year":"2019","unstructured":"Agca R, Hopman LHGA, Laan KCJ et al (2019) Cardiovascular event risk in rheumatoid arthritis is higher than in type 2 diabetes: a 15 year longitudinal study. J Rheumatol 47(3):316\u2013324. https:\/\/doi.org\/10.3899\/jrheum.180726","journal-title":"J Rheumatol"},{"issue":"9","key":"4754_CR38","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1136\/ard.2008.094151","volume":"68","author":"VP van Halm","year":"2009","unstructured":"van Halm VP, Peters MJL, Voskuyl AE et al (2009) Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis 68(9):1395\u20131400. https:\/\/doi.org\/10.1136\/ard.2008.094151","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4754_CR39","first-page":"73","volume":"36","author":"J Rueda-Gotor","year":"2018","unstructured":"Rueda-Gotor J, Llorca J, Corrales A et al (2018) Cardiovascular risk stratification in axial spondyloarthritis: carotid ultrasound is more sensitive than coronary artery calcification score to detect high-cardiovascular risk axial spondyloarthritis patients. Clin Exp Rheumatol 36(1):73\u201380","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"4754_CR40","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1007\/s00296-020-04691-5","volume":"40","author":"AD Jamthikar","year":"2020","unstructured":"Jamthikar AD, Gupta D, Puvvula A et al (2020) Cardiovascular risk assessment in patients with rheumatoid arthritis using carotid ultrasound B-mode imaging. Rheumatol Int 40(12):1921\u20131939. https:\/\/doi.org\/10.1007\/s00296-020-04691-5","journal-title":"Rheumatol Int"},{"issue":"4","key":"4754_CR41","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/acr.23875","volume":"72","author":"S Singh","year":"2020","unstructured":"Singh S, Fumery M, Singh AG et al (2020) Comparative risk of cardiovascular events with biologic and synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 72(4):561\u2013576. https:\/\/doi.org\/10.1002\/acr.23875","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10133","key":"4754_CR42","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1016\/S0140-6736(18)30664-0","volume":"391","author":"R Pylypchuk","year":"2018","unstructured":"Pylypchuk R, Wells S, Kerr A et al (2018) Cardiovascular disease risk prediction equations in 400 000 primary care patients in New Zealand: a derivation and validation study. Lancet 391(10133):1897\u20131907. https:\/\/doi.org\/10.1016\/S0140-6736(18)30664-0","journal-title":"Lancet"},{"issue":"1","key":"4754_CR43","doi-asserted-by":"publisher","first-page":"e000166","DOI":"10.1136\/rmdopen-2015-000166","volume":"2","author":"JC Branco","year":"2016","unstructured":"Branco JC, Rodrigues AM, Gouveia N et al (2016) Prevalence of rheumatic and musculoskeletal diseases and their impact on health-related quality of life, physical function and mental health in Portugal: results from EpiReumaPt\u2013 a national health survey. RMD Open 2(1):e000166. https:\/\/doi.org\/10.1136\/rmdopen-2015-000166","journal-title":"RMD Open"},{"issue":"8","key":"4754_CR44","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1023\/B:EJEP.0000036568.02655.f8","volume":"19","author":"V Kristman","year":"2004","unstructured":"Kristman V, Manno M, C\u00f4t\u00e9 P (2004) Loss to follow-up in cohort studies: how much is too much? Eur J Epidemiol 19(8):751\u2013760. https:\/\/doi.org\/10.1023\/B:EJEP.0000036568.02655.f8","journal-title":"Eur J Epidemiol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-020-04754-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-020-04754-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-020-04754-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T18:10:50Z","timestamp":1611598250000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-020-04754-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,3]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["4754"],"URL":"https:\/\/doi.org\/10.1007\/s00296-020-04754-7","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,3]]},"assertion":[{"value":"2 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Barkoudah reports research support from National Institutes of Health\/National Heart, Lung, and Blood Institute, Bristol Myers Squibb and Janssen, payments made to Brigham and Women\u2019s Hospital for performing clinical endpoints and Advisory Board fees from Bristol Myers Squibb, Janssen, Novartis, Pfizer and Portola, and travel expenses from Alexion; all outside he presented work. No other conflict of interest was identified.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approved by NOVA Medical School Ethics Committee and the National Committee for Data Protection.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}